Statins in the spectrum of neurologic disease J. David Orr OriginalPaper 31 January 2008 Pages: 11 - 18
Recognizing and improving patient nonadherence to statin therapy Humayun J. ChaudhryBrian McDermott OriginalPaper 31 January 2008 Pages: 19 - 24
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Eliot A. Brinton OriginalPaper 31 January 2008 Pages: 25 - 32
What is the evidence in favor of low-dose statin therapy in 2008? Karol E. Watson OriginalPaper 31 January 2008 Pages: 33 - 38
Do statins reduce events in patients with metabolic syndrome? Sarah P. TowneEddie Thara OriginalPaper 31 January 2008 Pages: 39 - 44
Pleiotropic effects: Should statins be considered an essential component in the treatment of dyslipidemia? Maureen E. MaysCarlos A. Dujovne OriginalPaper 31 January 2008 Pages: 45 - 52
Exenatide as a treatment for diabetes and obesity: Implications for cardiovascular risk reduction Derek D. MafongRobert R. Henry OriginalPaper 31 January 2008 Pages: 55 - 60
HIV therapy, metabolic syndrome, and cardiovascular risk Vivian PaoGrace A. LeeCarl Grunfeld OriginalPaper 31 January 2008 Pages: 61 - 70
Rimonabant: New data and emerging experience Suzanne M. WrightCarolien DikkersLouis J. Aronne OriginalPaper 31 January 2008 Pages: 71 - 78
New approaches to therapy with omega-3 fatty acids Puneet KakarTimothy WatsonGregory Y. H. Lip OriginalPaper 31 January 2008 Pages: 79 - 87
Liver X receptors as therapeutic targets in metabolism and atherosclerosis Takashi NomiyamaDennis Bruemmer OriginalPaper 31 January 2008 Pages: 88 - 95